Publikationen und Abstracts

R. Riedel, J. Fassunke, HLTumbrink, A. Scheel, C. Heydt, L. Hieggelke, M. Scheffler, A. Heimsoeth, L. Nogova, S. Michels, J-P.Weber, R. Fischer, A. Eisert, T. Westphal, D. Schaufler, J. Siemanowski, M. Ihle, S. Wagener-Ryczek, R. Castiglione, R. Pappesch, J. Rehker, J. Jürgens, E. Stoelben, A. Bunck, C. Kobe, S. Merkelbach-Bruse, M. Sos, R. Büttner, J. Wolf
Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors.
European Journal of Cancer, 2023, 179. Jg., S. 124-135.doi: 10.1016/j.ejca.2022.11.010.

R. Fischer, J. George, A. Scheel, H. Schloesser, P. Brossart, W. Engel-Riedel, F. Griesinger, C. Grohé, J.K. Kern, J. Panse, M. Sebastian, M. Serke, R. Wiewrodt, S. Michels, L. Nogova, R. Riedel, J-P. Weber, R. Büttner, R. Thomas, J. Wolf
Abstract: 1028P BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response – results from the NSCLC cohort
Annals of Oncology 33, 2022, S1025. Doi: 10.1016/j.annonc.2022.07.1154

M. Glaser, C. von Levetzow, S. Michels, L. Nogova, M. Katzenmeier, C. Wömpner, J. Schmitz, E. Bitter, I. Terjung, E. Passmann, D. Schaufler, A. Eisert, R. Fischer, R. Riedel J.-P. Weber, S. Hahne, S. Merkelbach-Bruse, R. Büttner, J. Wolf M. Scheffler
EP08.02-114 Comprehensive Analysis of ROS1 Aberrations without Rearrangements in Non-small cell Lung Cancer Patients.
Journal of Thoracic Oncology, 2022, 17. Jg., Nr. 9, S. S456.doi: 10.1016/j.jtho.2022.07.797

M. Glaser, C. von Levetzow, S. Michels, L. Nogova, M. Katzenmeier, C. Wömpner, J. Schmitz, E. Bitter, I. Terjung, E. Passmann, D. Schaufler, A. Eisert, R. Fischer, R. Riedel J.-P. Weber, S. Hahne, S. Merkelbach-Bruse, R. Büttner, J. Wolf M. Scheffler
52P ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics. 
Annals of Oncology, 2022, 33. Jg., S. S56-S57

M. Scheffler, M. Dugan, M.M. Saleh, S. Koleczko, J. Brägelmann, C. Arolt, L. Nogova, R. Riedel, S. Michels, A. Eisert, R. Fischer
H. Scharpenseel, J.-P. Weber, A.H. Scheel, S. Merkelbach-Bruse, R. Büttner, F. Lafleur, R. Wild, L. Catanzariti, A.M. Hillmer, J. Wolf
EP08. 02-106 KEAP1/NFE2L2 Transcriptomic Signature Predicts Survival in Advanced Stage NSCLC Patients Without Actionable Driver Mutations. 
Journal of Thoracic Oncology, 2022, 17. Jg., Nr. 9, S. S451-S452.

J-P. Weber, M. Wermke.
Small cell lung cancer-Established standards and new approaches. 
Innere medizin (Heidelberg, Germany), 2022, 63. Jg., Nr. 7, S. 724-730.

J-P. Weber, M. Wermke.
Kleinzelliges Lungenkarzinom–Etablierte Standards und neue Ansätze. 
best practice onkologie, 2022, 17. Jg., Nr. 11, S. 550-557.

H. Scharpenseel, F. Malchers, I. Terjung, A. Hillmer, S. Merkelbach-Bruse, A. Scheel, J. Siemanowski, M. Scheffler, R. Riedel, A. Eisert, S. Michels, R. Fischer, J-P. Weber, T. Westphal, A. Kron, J. Sueptitz, R. Thomas, R. Buettner, J. Wolf, L. Nogova
Screening of FGFR patients for FGFR directed clinical trials in Network Genomic Medicine (NGM): Real-world data. 
2022

Schaufler D, Ast DF, Tumbrink HL, Abedpour N, Maas L, Schwäbe AE, Spille I, Lennartz S, Fassunke J, Aldea M, Besse B, Planchard D, Nogova L, Michels S, Kobe C, Persigehl T, Westphal T, Koleczko S, Fischer R, Weber JP, Altmüller J, Thomas RK, Merkelbach-Bruse S, Gautschi O, Mezquita L, Büttner R, Wolf J, Peifer M, Brägelmann J, Scheffler M, Sos ML. 
Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer. 
NPJ Precis Oncol. 2021 Dec 17;5(1):102. doi: 10.1038/s41698-021-00241-9

Scheffler M, Holzem A, Kron A, Nogova L, Ihle MA, von Levetzow C, Fassunke J,  Wömpner C, Bitter E, Koleczko S, Abdulla DSY, Michels S, Fischer R, Riedel R, Weber JP, Westphal T, Gerigk U, Kern J, Kaminsky B, Randerath W, Kambartel. KO, Merkelbach-Bruse S, Büttner R, Wolf J. 
Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations. 
Lung Cancer. 2020 Jun;144:40-48. doi: 10.1016/j.lungcan.2020.04.020.

Coch C, Stümpel JP et al., 
RIG-I Activation Protects and Rescues from Lethal 
Influenza Virus Infection and Bacterial Superinfection. 
Mol Ther. 2017 Sep 6;25(9):2093-2103. doi: 10.1016/j.ymthe.2017.07.003

Batty P, Austin SK, Khair K, Millar CM, Palmer B, Rangarajan S, Stümpel JP, Thanigaikumar M, Yee TT, Hart DP. 
Treatment burden, haemostatic strategies and real world inhibitor screening practice in non-severe
haemophilia A. 
Br J Haematol. 2017 Mar;176(5):796-804. doi: 10.1111/bjh.14543. 

Schuberth-Wagner C, Ludwig J, Bruder AK, Herzner AM, Zillinger T, Goldeck M, Schmidt T, Schmid-Burgk JL, Kerber R, Wolter S, Stümpel JP, Roth A, Bartok E, Drosten C, Coch C, Hornung V, Barchet W, Kümmerer BM, Hartmann G, Schlee, M. 
A Conserved Histidine in the RNA Sensor RIG-I Controls Immune Tolerance to N1-2’O-Methylated Self RNA. 
Immunity. 2015 Jul 21;43(1):41-51. doi: 10.1016/j.immuni.2015.06.015. Epub 2015 Jul 14. PMID: 26187414; PMCID: PMC7128463.